WallStreetZenWallStreetZen

NASDAQ: RNAC
Cartesian Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for RNAC

Based on 2 analysts offering 12 month price targets for Cartesian Therapeutics Inc.
Min Forecast
$42.00+134.51%
Avg Forecast
$51.00+184.76%
Max Forecast
$60.00+235.01%

Should I buy or sell RNAC stock?

Based on 2 analysts offering ratings for Cartesian Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RNAC stock forecasts and price targets.

RNAC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-10
lockedlocked$00.00+00.00%2024-03-18

1 of 1

Forecast return on equity

Is RNAC forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is RNAC forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

RNAC revenue forecast

What is RNAC's revenue in the next 1 years based on estimates from 2 analysts?
Avg 1 year Forecast
$61.6M+136.69%
RNAC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RNAC revenue growth forecast

How is RNAC forecast to perform vs Biotechnology companies and vs the US market?
Company
36.39%
Industry
38.03%
Market
10.06%
RNAC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RNAC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RNAC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNAC$17.91$51.00+184.76%Buy
PDSB$2.65$17.33+555.31%Strong Buy
ARMP$2.67$7.00+162.66%Buy
IOBT$1.48$8.00+440.54%Buy
BRNS$2.51$8.00+218.73%Buy

Cartesian Therapeutics Stock Forecast FAQ

Is Cartesian Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: RNAC) stock is to Buy RNAC stock.

Out of 2 analysts, 0 (0%) are recommending RNAC as a Strong Buy, 2 (100%) are recommending RNAC as a Buy, 0 (0%) are recommending RNAC as a Hold, 0 (0%) are recommending RNAC as a Sell, and 0 (0%) are recommending RNAC as a Strong Sell.

If you're new to stock investing, here's how to buy Cartesian Therapeutics stock.

What is RNAC's revenue growth forecast for 2024-2024?

(NASDAQ: RNAC) Cartesian Therapeutics's forecast annual revenue growth rate of 36.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.06%.

Cartesian Therapeutics's revenue in 2024 is $26,004,000.

In 2024, RNAC is forecast to generate $332,264,565 in revenue, with the lowest revenue forecast at $107,965,740 and the highest revenue forecast at $556,563,390.

What is RNAC's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RNAC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is RNAC's Price Target?

According to 2 Wall Street analysts that have issued a 1 year RNAC price target, the average RNAC price target is $51.00, with the highest RNAC stock price forecast at $60.00 and the lowest RNAC stock price forecast at $42.00.

On average, Wall Street analysts predict that Cartesian Therapeutics's share price could reach $51.00 by Apr 10, 2025. The average Cartesian Therapeutics stock price prediction forecasts a potential upside of 184.76% from the current RNAC share price of $17.91.

What is RNAC's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RNAC) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.